Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry

Am Heart J. 2021 Oct:240:58-62. doi: 10.1016/j.ahj.2021.04.017. Epub 2021 May 24.

Abstract

Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Oral
  • Aged
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / drug therapy*
  • Dabigatran / therapeutic use
  • Female
  • Humans
  • Male
  • Practice Patterns, Physicians'
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Pyridones / therapeutic use
  • Registries
  • Risk Factors
  • Rivaroxaban / therapeutic use
  • Stroke / prevention & control*
  • Thiazoles / therapeutic use
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Pyrazoles
  • Pyridines
  • Pyridones
  • Thiazoles
  • apixaban
  • Warfarin
  • Rivaroxaban
  • Dabigatran
  • edoxaban